MARKET

OPK

OPK

OPKO Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.820
+0.030
+0.79%
After Hours: 3.760 -0.06 -1.57% 18:37 09/21 EDT
OPEN
3.800
PREV CLOSE
3.790
HIGH
3.870
LOW
3.775
VOLUME
2.06M
TURNOVER
--
52 WEEK HIGH
6.27
52 WEEK LOW
3.020
MARKET CAP
2.60B
P/E (TTM)
34.45
1D
5D
1M
3M
1Y
5Y
CEO And Chairman Of Opko Health Makes $346.44 Thousand Buy
Phillip Frost M.D., Individually And As Trustee, CEO And Chairman at Opko Health (NASDAQ:OPK), made a large insider buy on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesd...
Benzinga · 6d ago
OPKO Health (OPK) Forms JV, Establishes Presence in China
OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.
Zacks · 6d ago
BRIEF-LeaderMed Group, OPKO Health Form Joint Venture
reuters.com · 09/14 12:55
LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories
SHANGHAI and MIAMI, Sept. 14, 2021 (GLOBE NEWSWIRE) -- LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company focused on diagnostics and phar...
GlobeNewswire · 09/14 12:00
Opko Health, LeaderMed Form Joint Venture to Commercialize Two Drugs in Asia
MT Newswires · 09/14 09:00
New COVID-19 testing mandate could strain already stretched supplies
A new six-point plan, announced by President Joe Biden on Thursday to fight the pandemic requiring COVID-19 vaccinations or regular testing for nearly two-thirds of U.S. employees could overwhelm the
Seekingalpha · 09/10 12:27
Hancock Horizon Burkenroad Small Cap Fund Buys Earthstone Energy Inc, Waitr Holdings Inc, OPKO ...
GuruFocus News · 09/04 06:38
Colony Family Offices, LLC Buys Dimensional U.S. ...
GuruFocus News · 09/01 22:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OPK. Analyze the recent business situations of OPKO Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OPK stock price target is 6.60 with a high estimate of 8.50 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 341
Institutional Holdings: 201.19M
% Owned: 29.54%
Shares Outstanding: 681.16M
TypeInstitutionsShares
Increased
59
10.60M
New
33
3.23M
Decreased
70
9.03M
Sold Out
39
3.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.40%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Chief Executive Officer/Director
Phillip Frost
Vice Chairman/Chief Technology Officer/Director
Jane Hsiao
Chief Financial Officer/Senior Vice President/Chief Accounting Officer/Treasurer
Adam Logal
Corporate Executive/Director
Jon Cohen
Corporate Executive
Charles Bishop
Corporate Executive
Tony Cruz
Corporate Executive
Geoff Monk
Corporate Executive
Katherine Stueland
Executive Vice President/Director
Steven Rubin
Independent Director
Robert Fishel
Independent Director
Richard Krasno
Independent Director
Prem Lachman
Independent Director
Richard Lerner
Independent Director
Roger Medel
Independent Director
John Paganelli
Independent Director
Richard Pfenniger
Independent Director
Alice Yu
No Data
About OPK
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Webull offers kinds of Opko Health Inc. stock information, including NASDAQ:OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.